PART I Item 1. Bus iness. Overview We are a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. We have a diverse portfolio of product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. We were founded in April 2016 and are led by a manage...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001193125-26-097558 | EDGAR | 95K words |
| 2025-04-15 | 2024-12-31 | 0000950170-25-053945 | EDGAR | — |
| 2024-03-18 | 2023-12-31 | 0000950170-24-032819 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008456 | EDGAR | — |
| 2022-03-14 | 2021-12-31 | 0000950170-22-003582 | EDGAR | — |
| 2021-03-22 | 2020-12-31 | 0001564590-21-014593 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274234 | EDGAR | 65K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108888 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064463 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124479 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095461 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058657 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062997 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042439 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021984 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024531 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016486 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0000950170-22-009335 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001193125-26-117888 | EDGAR | 2K words |
| 2026-03-09 | 0001193125-26-097561 | EDGAR | — |
| 2026-02-05 | 0001193125-26-039399 | EDGAR | — |
| 2026-01-08 | 0001193125-26-007038 | EDGAR | — |
| 2025-12-15 | 0001193125-25-318488 | EDGAR | — |
| 2025-12-12 | 0001193125-25-317532 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274216 | EDGAR | — |
| 2025-10-17 | 0001193125-25-242488 | EDGAR | — |
| 2025-10-08 | 0001193125-25-234516 | EDGAR | — |
| 2025-08-14 | 0000950170-25-108868 | EDGAR | — |
94 total filings indexed. 66 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001683553 |
| Ticker | SPRB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.sprucebiosciences.com |
| Listed | 2020-10-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report